Next Virginia

Fairfax, Virginia 22301

74 studies enrolling now · 114 studies all time

What they study most

1st Line NSCLC, ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, Acquired Resistance to KRAS G12C Inhibitor, Adenocarcinoma, Adenoid Cystic Carcinoma, Advanced Breast Cancer, Advanced Cancer, Advanced Endometrial Carcinoma, Advanced Gastric Cancer, Advanced Gastric Carcinoma

Studies at this site

• A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Recruiting now
• Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors — Recruiting now
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) — Recruiting now
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — Recruiting now
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — Recruiting now
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors — Recruiting now
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors — Recruiting now
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors — Recruiting now
• Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies — Recruiting now
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Recruiting now
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
• First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies — Recruiting now
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer — Recruiting now
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
• A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors — Recruiting now
• First In Human Study of CX-2051 in Advanced Solid Tumors — Recruiting now
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Recruiting now
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — Recruiting now
• Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer — Recruiting now
• Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma — Recruiting now
• First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer — Recruiting now
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer — Recruiting now
• A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer — Recruiting now
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors — Recruiting now
• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors — Recruiting now
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors — Recruiting now
• A Study of PYX-201 in Advanced Solid Tumors — Recruiting now
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation — Recruiting now
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
• Study of XB010 in Subjects With Solid Tumors — Recruiting now
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — Recruiting now
• Study of GS-5319 in Adults With Solid Tumors — Recruiting now
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors — Recruiting now
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies — Recruiting now
• A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors — Recruiting now
• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations — Recruiting now
• A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies — Recruiting now
• A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors — Recruiting now
• A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours — Recruiting now
• Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors — Recruiting now
• A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation — Recruiting now